XENON PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
XENON PHARMACEUTICALS INC. (XENE) reported Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount of $148.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherReconcilingItems · last filed 2024-02-29
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2023 was $148.00K, a 43.94% decline from fiscal 2022.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2022 was $264.00K.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2021 was -$506.00K.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2020 was -$432.00K, a 199.77% decline from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month as first filed |
|---|---|---|
| 2023-12-31 | $148.00K 10-K · filed 2024-02-29 | |
| 2022-12-31 | $264.00K 10-K · filed 2024-02-29 | |
| 2021-12-31 | -$506.00K 10-K · filed 2024-02-29 | |
| 2020-12-31 | -$432.00K 10-K · filed 2023-03-01 | |
| 2019-12-31 | $433.00K 10-K · filed 2021-03-01 | |
| 2018-12-31 | -$54.00K 10-K · filed 2020-03-09 | -$70.00K 10-K · filed 2019-03-06 |
| 2017-12-31 | $350.00K 10-K · filed 2019-03-06 | |
| 2016-12-31 | -$72.00K 10-K · filed 2018-03-07 | |
| 2015-12-31 | -$995.00K 10-K · filed 2018-03-07 | |
| 2014-12-31 | $1.25M 10-K · filed 2017-03-08 | |
| 2013-12-31 | $655.00K 10-K · filed 2016-03-08 | |
| 2012-12-31 | $32.00K 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |